Trial results

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

NCT05413369 on ClinicalTrials.gov · last registry update 2025-09-24

Finished 20 October 2023, after enrolling 582 people. Primary outcome, as filed: Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P3

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Sanofi

Sponsor type

Industry

Enrollment

582

Started

2022-07-07

Primary completion

2023-10-20 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.